Browse studies

Find your next paid study

9 recruiting studies matching your filters

A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Patients With Moderately to Severely Active Crohn's Disease

This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as R…

Moderately to Severely Active Crohns Disease

Estimated

~$10 – $7,500

Hoffmann-La RocheNCT06819891

Phase 3

CNTO1959ISD3001: A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study to Evaluate the Safety of Guselkumab in Pediatric Participants With Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis

The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative co…

Crohns DiseaseColitis, UlcerativeArthritis, Psoriatic+1 more

Estimated

~$10 – $8,750

Janssen Research & Development, LLCNCT06663332

Phase 3

A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Crohn's Disease

This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance therapy wi…

Moderately to Severely Active Crohns Disease

Estimated

~$10 – $7,500

Hoffmann-La RocheNCT06819878

Phase 2

The NAGIC Study: Multi-center, Randomized, Double-blind, Placebo-controlled Cross-over Study of Oral N-acetylglucosamine in Ileal/Ileocolonic Crohn's Disease

Protein glycosylation is a critical post-translational modification that regulates protein trafficking and protein-protein interactions impacting a host of phy…

Crohns Disease

Estimated

~$10 – $6,250

Johns Hopkins UniversityNCT07225998

Phase 3

A Phase III Randomized Double-Blind Multi-Center Treat-Through Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Children Aged 2-17 Years With Moderately to Severely Active Crohn's Disease

This phase III, double-blind, multi-center treat-through study will evaluate the efficacy and safety of Afimkibart (also known as RO7790121) in children with m…

Moderately to Severely Active Crohns Disease

Estimated

~$10 – $7,500

Hoffmann-La RocheNCT07298421

Development of a Novel Endoscopic Index and Patient-reported Outcome Measure for Clinical Trials in Participants With Permanent Ileostomy

To date, patients with Crohn's Disease (CD) and permanent ileostomies have been excluded from clinical trials for new treatments. To allow this patient populat…

Crohns Disease

Estimated

~$10 – $1,050

Alimentiv Inc.NCT06670638

Phase 1

A Phase 1/2a, Open Label, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of TRX103 in Subjects With Moderate to Severe Treatment-Refractory Crohn's Disease

This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn's Disease (CD). T…

Crohns Disease

Estimated

~$10 – $8,750

Tr1X, Inc.NCT06721962

PLANET: Exploring the Role of Plastics and Toxins in Intestinal Inflammation

The PLANET Study aims to determine the impact of microplastics on intestinal inflammation and gut microbiome in order to understand the role of this pollutant …

Crohns DiseasePregnancyInflammatory Bowel Disease

Estimated

~$10 – $750

Icahn School of Medicine at Mount SinaiNCT06001450

Phase 4

Evaluating the Efficacy and Safety of Mirikizumab in Adults Over 60 With Moderate to Severe Crohn's Disease and Ulcerative Colitis: A Phase IV Multicenter Interventional Study

This research study looks at how safe and effective a medicine called Mirikizumab is for treating older adults (aged 60 and above) who have moderate to severe …

Crohn Disease (CD)Crohns DiseaseUlcerative Colitis (UC)

Estimated

~$10 – $7,500

Rubix LSNCT07059130